As discussed previously, I anticipate FreeStyle Libre will continue to drive the overall growth in the medical device segment. Due to the strong performance during the quarter, Abbott raised the ...

Shares of Abbott rose 2% in afternoon trade. The company's medical devices unit generated $4.75 billion in sales for the third quarter, above analysts' average estimate of $4.68 billion ...

(Reuters) -Abbott Laboratories slightly ... monitoring products and other medical devices. Sales of continuous glucose ...

The device is similar to Abbott’s FreeStyle Libre, which people with diabetes have been using for years to track their glucose levels. Each disc remains on the arm for 14 days before it must be ...

Oct 16 (Reuters) - Abbott Laboratories (ABT.N), opens new tab slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong demand ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have benefited CGMs such as Abbott's popular FreeStyle Libre. The company's ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have benefited CGMs such as Abbott's popular FreeStyle Libre. The company's CGM ...

Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical devices. Sales were also higher at its pharmaceutical unit, but fell at its diagnostics and ...

A major development towards the goal of patient and provider choice, the cloud-to-cloud integration will provide an automatic stream of data from patients using Abbott’s FreeStyle Libre ...

Sales growth in the medical devices segment drove Abbott Laboratories’ expectations-beating revenue in the past financial quarter as the company faces lower demand for COVID-19 tests ...